JPWO2020186207A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020186207A5 JPWO2020186207A5 JP2021554696A JP2021554696A JPWO2020186207A5 JP WO2020186207 A5 JPWO2020186207 A5 JP WO2020186207A5 JP 2021554696 A JP2021554696 A JP 2021554696A JP 2021554696 A JP2021554696 A JP 2021554696A JP WO2020186207 A5 JPWO2020186207 A5 JP WO2020186207A5
- Authority
- JP
- Japan
- Prior art keywords
- cedna vector
- itrs
- stem
- pharmaceutical composition
- regions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025016352A JP2025073123A (ja) | 2019-03-13 | 2025-02-03 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
| JP2025172911A JP2026002894A (ja) | 2019-03-13 | 2025-10-14 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962817904P | 2019-03-13 | 2019-03-13 | |
| US62/817,904 | 2019-03-13 | ||
| US201962856432P | 2019-06-03 | 2019-06-03 | |
| US62/856,432 | 2019-06-03 | ||
| PCT/US2020/022738 WO2020186207A2 (en) | 2019-03-13 | 2020-03-13 | Non-viral dna vectors and uses thereof for expressing fviii therapeutics |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025016352A Division JP2025073123A (ja) | 2019-03-13 | 2025-02-03 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
| JP2025172911A Division JP2026002894A (ja) | 2019-03-13 | 2025-10-14 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022524434A JP2022524434A (ja) | 2022-05-02 |
| JPWO2020186207A5 true JPWO2020186207A5 (enExample) | 2023-03-22 |
| JP7795357B2 JP7795357B2 (ja) | 2026-01-07 |
Family
ID=72426821
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021554696A Active JP7795357B2 (ja) | 2019-03-13 | 2020-03-13 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
| JP2025016352A Pending JP2025073123A (ja) | 2019-03-13 | 2025-02-03 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
| JP2025172911A Pending JP2026002894A (ja) | 2019-03-13 | 2025-10-14 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025016352A Pending JP2025073123A (ja) | 2019-03-13 | 2025-02-03 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
| JP2025172911A Pending JP2026002894A (ja) | 2019-03-13 | 2025-10-14 | Ｆｖｉｉｉ治療薬を発現するための非ウイルス性ｄｎａベクターおよびその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12338275B2 (enExample) |
| EP (1) | EP3938523A4 (enExample) |
| JP (3) | JP7795357B2 (enExample) |
| KR (1) | KR20210151785A (enExample) |
| CN (1) | CN113874513A (enExample) |
| AU (1) | AU2020234713A1 (enExample) |
| BR (1) | BR112021017853A2 (enExample) |
| CA (1) | CA3133255A1 (enExample) |
| IL (1) | IL286284A (enExample) |
| MA (1) | MA55313A (enExample) |
| MX (1) | MX2021011039A (enExample) |
| SG (1) | SG11202109850SA (enExample) |
| WO (1) | WO2020186207A2 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI904068B (zh) | 2017-08-09 | 2025-11-11 | 美商生物化學醫療公司 | 核酸分子及其用途 |
| WO2020033863A1 (en) | 2018-08-09 | 2020-02-13 | Bioverativ Therapeutics Inc. | Nucleic acid molecules and uses thereof for non-viral gene therapy |
| EP4189098A1 (en) | 2020-07-27 | 2023-06-07 | Anjarium Biosciences AG | Compositions of dna molecules, methods of making therefor, and methods of use thereof |
| US20220356490A1 (en) * | 2020-08-23 | 2022-11-10 | Bioverativ Therapeutics Inc. | Baculovirus expression system |
| WO2023069948A1 (en) * | 2021-10-18 | 2023-04-27 | Flagship Pioneering Innovations Vii, Llc | Dna compositions and related methods |
| US20240335564A1 (en) * | 2021-11-02 | 2024-10-10 | Gritgen Therapeutics Limited | Isolated nucleic acid molecule and use thereof |
| JP2023089774A (ja) * | 2021-12-16 | 2023-06-28 | 株式会社三洋物産 | 遊技機 |
| WO2023135273A2 (en) * | 2022-01-14 | 2023-07-20 | Anjarium Biosciences Ag | Compositions of dna molecules encoding factor viii, methods of making thereof, and methods of use thereof |
| WO2025110984A1 (en) * | 2023-11-21 | 2025-05-30 | Hydrogene Therapeutics, Inc. | Compositions and methods for treating wilson's disease |
| KR20260011950A (ko) | 2024-07-17 | 2026-01-26 | 이민형 | 수질 시료 채취 드론 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009067548A1 (en) * | 2007-11-19 | 2009-05-28 | The Regents Of The University Of California | Novel assay for inhibitors of egfr |
| CN102573915B (zh) * | 2009-04-30 | 2015-02-18 | 赛托斯生物技术公司 | 流感血凝素组合物及其用途 |
| EP2500434A1 (en) | 2011-03-12 | 2012-09-19 | Association Institut de Myologie | Capsid-free AAV vectors, compositions, and methods for vector production and gene delivery |
| DK2956477T4 (da) * | 2013-02-15 | 2024-04-15 | Bioverativ Therapeutics Inc | Optimeret faktor viii-gen |
| ES2813698T3 (es) * | 2013-09-12 | 2021-03-24 | Biomarin Pharm Inc | Vectores de AAV que comprenden un gen que codifica el factor VIII |
| GB2526339A (en) * | 2014-05-21 | 2015-11-25 | Imp Innovations Ltd | Lentiviral vectors |
| CN108136048A (zh) * | 2015-08-03 | 2018-06-08 | 米奥多巴有限公司 | 左旋多巴的系统合成和调节 |
| BR112018006074A2 (pt) | 2015-09-24 | 2018-10-09 | Biomarin Pharm Inc | vetores de fator viii de vírus adeno-associado, partículas virais associadas e formulações terapêuticas compreendendo as mesmas |
| KR102766526B1 (ko) | 2015-10-28 | 2025-02-13 | 상가모 테라퓨틱스, 인코포레이티드 | 간-특이적 작제물인, 인자 viii 발현 카세트 및 이의 사용 방법 |
| PE20231949A1 (es) * | 2015-10-30 | 2023-12-05 | Spark Therapeutics Inc | VARIANTES DEL FACTOR VIII REDUCIDO CON CpG, COMPOSICIONES Y METODOS Y USOS PARA EL TRATAMIENTO DE TRASTORNOS DE LA HEMOSTASIA |
| EP3423110B1 (en) | 2016-03-03 | 2021-08-11 | University of Massachusetts | Closed-ended linear duplex dna for non-viral gene transfer |
| WO2017180857A1 (en) | 2016-04-15 | 2017-10-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating hemophilia a |
| BR112020001979A2 (pt) * | 2017-08-01 | 2020-08-18 | Spark Therapeutics, Inc. | métodos de terapia genética do fator viii (fviii) |
| TWI904068B (zh) * | 2017-08-09 | 2025-11-11 | 美商生物化學醫療公司 | 核酸分子及其用途 |
-
2020
- 2020-03-13 JP JP2021554696A patent/JP7795357B2/ja active Active
- 2020-03-13 BR BR112021017853A patent/BR112021017853A2/pt unknown
- 2020-03-13 KR KR1020217029545A patent/KR20210151785A/ko active Pending
- 2020-03-13 WO PCT/US2020/022738 patent/WO2020186207A2/en not_active Ceased
- 2020-03-13 AU AU2020234713A patent/AU2020234713A1/en active Pending
- 2020-03-13 SG SG11202109850S patent/SG11202109850SA/en unknown
- 2020-03-13 US US17/437,123 patent/US12338275B2/en active Active
- 2020-03-13 CN CN202080036209.7A patent/CN113874513A/zh active Pending
- 2020-03-13 MA MA055313A patent/MA55313A/fr unknown
- 2020-03-13 CA CA3133255A patent/CA3133255A1/en active Pending
- 2020-03-13 EP EP20769344.1A patent/EP3938523A4/en active Pending
- 2020-03-13 MX MX2021011039A patent/MX2021011039A/es unknown
-
2021
- 2021-09-12 IL IL286284A patent/IL286284A/en unknown
-
2025
- 2025-02-03 JP JP2025016352A patent/JP2025073123A/ja active Pending
- 2025-05-21 US US19/214,171 patent/US20250282848A1/en active Pending
- 2025-10-14 JP JP2025172911A patent/JP2026002894A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024009857A5 (enExample) | ||
| JP2021003120A5 (enExample) | ||
| JP2017509632A5 (enExample) | ||
| JP2022190081A5 (enExample) | ||
| JP2020532981A5 (enExample) | ||
| JP2021087431A5 (enExample) | ||
| JP2018522529A5 (enExample) | ||
| HRP20192141T1 (hr) | Genska terapija za retinitis pigmentosa | |
| IL299325B2 (en) | Acid-alpha glucosidase variants and uses thereof | |
| JP2019503649A5 (enExample) | ||
| JP2020519284A5 (enExample) | ||
| JP2020533276A5 (enExample) | ||
| JP2024099770A5 (enExample) | ||
| CA3158518A1 (en) | Triple function adeno-associated virus (aav)vectors for the treatment of c9orf72 associated diseases | |
| JP2017529395A5 (enExample) | ||
| JPWO2021067448A5 (enExample) | ||
| JPWO2020186207A5 (enExample) | ||
| JPWO2019165050A5 (enExample) | ||
| JPWO2020168222A5 (enExample) | ||
| JPWO2020186150A5 (enExample) | ||
| JPWO2020028816A5 (enExample) | ||
| Youjin et al. | The treatment of hemophilia A: from protein replacement to AAV-mediated gene therapy | |
| JPWO2021195214A5 (enExample) | ||
| JP2023059858A5 (enExample) | ||
| JPWO2021195218A5 (enExample) |